(5-Isopropyl-1,3,4-oxadiazol-2-YL)methanol | 1211131-67-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: (5-Isopropyl-1,3,4-oxadiazol-2-YL)methanol
• 英文别名: (5-propan-2-yl-1,3,4-oxadiazol-2-yl)methanol
• CAS: 1211131-67-7
• 化学式: C₆H₁₀N₂O₂
• mdl: MFCD13188553
• 分子量: 142.16
• InChiKey: RXTQZBAFYARQJE-UHFFFAOYSA-N

物化性质

• 沸点：
  252.3±42.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.666
• 拓扑面积：
  59.2
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Heteroaromatic Compounds As Inhibitors Of Stearoyl-Coenzyme A Delta-9 Desaturase
  申请人：Black Cameron

  公开号：US20090118296A1

  公开（公告）日：2009-05-07

  Heteroaromatic compounds of structural formula (I) are selective inhibitors of stearoyl-coenzyme A delta-9 desaturase (SCD1) relative to other known stearoyl-coenzyme A desaturases. The compounds of the present invention are useful for the prevention and treatment of conditions related to abnormal lipid synthesis and metabolism, including cardiovascular disease; atherosclerosis; lipid disorders; obesity; diabetes; neurological disease; metabolic syndrome; insulin resistance; and fatty liver disease.

  结构式（I）的杂环芳香化合物是选择性的硬脂酰辅酶A-Δ9-脱饱和酶（SCD1）抑制剂，相对于其他已知的硬脂酰辅酶A脱饱和酶。本发明的化合物对于预防和治疗与异常脂质合成和代谢有关的疾病非常有用，包括心血管疾病、动脉粥样硬化、脂质代谢紊乱、肥胖症、糖尿病、神经系统疾病、代谢综合征、胰岛素抵抗和脂肪肝病。
• HETEROCYCLIC COMPOUNDS
  申请人：SHIONOGI & CO., LTD.

  公开号：US20140249159A1

  公开（公告）日：2014-09-04

  The invention relates to compounds of Formula I: wherein Ar 1 , Ar 2 , Ar 3 , L 1 , L 2 , Y, Z and v are defined in the specification, and pharmaceutically acceptable derivatives thereof, compositions comprising an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof, and methods for treating or preventing a condition such as pain, UI, an ulcer, IBD and IBS, comprising administering to an animal in need thereof an effective amount of a compound of Formula I or a pharmaceutically acceptable derivative thereof.

  本发明涉及式I的化合物：其中Ar1，Ar2，Ar3，L1，L2，Y，Z和v在说明书中有定义，以及其药学上可接受的衍生物，包括含有式I的化合物或其药学上可接受的衍生物的有效量的组合物，以及治疗或预防疼痛，尿失禁，溃疡，炎症性肠病和肠易激综合征等疾病的方法，包括向需要治疗的动物中给予式I的化合物或其药学上可接受的衍生物的有效量。
• HETEROCYCLIC COMPOUNDS AS NAV CHANNEL INHIBITORS AND USES THEREOF
  申请人：Merck Patent GmbH

  公开号：US20150266862A1

  公开（公告）日：2015-09-24

  The present invention relates to heterocyclic compounds, and pharmaceutically acceptable compositions thereof, useful as Nav1.6 inhibitors.

  本发明涉及杂环化合物及其药学上可接受的组合物，作为Nav1.6抑制剂有用。
• Therapeutic compounds and uses thereof
  申请人：GENENTECH, INC.

  公开号：US10202378B2

  公开（公告）日：2019-02-12

  The present invention relates to compounds of formula (I): and to salts thereof, wherein R1-R6 have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of TAF1. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various TAF1-mediated disorders.

  本发明涉及式（I）化合物： 及其盐，其中 R1-R6 具有说明书中定义的任一值，以及其组合物和用途。这些化合物可用作 TAF1 的抑制剂。还包括包含式（I）化合物或其药学上可接受的盐的药物组合物，以及使用此类化合物和盐治疗各种TAF1介导的疾病的方法。
• Heterocyclic compounds as NaV channel inhibitors and uses thereof
  申请人：Merck Patent GmbH

  公开号：US10377745B2

  公开（公告）日：2019-08-13

  The present invention relates to heterocyclic compounds, and pharmaceutically acceptable compositions thereof, useful as Nav1.6 inhibitors.

  本发明涉及可用作 Nav1.6 抑制剂的杂环化合物及其药学上可接受的组合物。